Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00320918
Status:
TERMINATED
Last Update Posted:
2024-01-12
First Post:
2006-04-28
Brief Title:
Chart Review UnresectableMetastatic Cholangiocarcinoma Treated With Irinotecan Capecitabine and Celecoxib
Sponsor:
University of New Mexico
Organization:
University of New Mexico
Study Overview
Official Title:
Chart Review on Patients With UnresectableMetastatic Cholangiocarcinoma Treated in the UNM Cancer Center With a Combination of Irinotecan Capecitabine and Celecoxib
Status:
TERMINATED
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
This was a Chart Review only and was entered in the system in error
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Chart Review on Patients with unresectablemetastatic cholangiocarcinoma treated in the UNM Cancer Center with a combination of irinotecan capecitabine and celecoxib
Detailed Description:
As above
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None